345 related articles for article (PubMed ID: 26008605)
1. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
2. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
[TBL] [Abstract][Full Text] [Related]
3. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
5. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
6. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
7. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
8. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ
Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266
[TBL] [Abstract][Full Text] [Related]
9. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
10. Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.
Hagemann C; Fuchs S; Monoranu CM; Herrmann P; Smith J; Hohmann T; Grabiec U; Kessler AF; Dehghani F; Löhr M; Ernestus RI; Vince GH; Stein U
Neuro Oncol; 2013 Dec; 15(12):1696-709. PubMed ID: 24220141
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.
Lee D; Suh YL; Park TI; Do IG; Seol HJ; Nam DH; Kim ST
J Surg Oncol; 2013 May; 107(6):646-52. PubMed ID: 22926763
[TBL] [Abstract][Full Text] [Related]
12. Heparanase expression of glioma in human and animal models.
Hong X; Nelson KK; deCarvalho AC; Kalkanis SN
J Neurosurg; 2010 Aug; 113(2):261-9. PubMed ID: 19835469
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD40 ligand in CD40-positive murine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2004; 24(5A):2713-6. PubMed ID: 15517876
[TBL] [Abstract][Full Text] [Related]
14. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of costimulatory molecules CD40/CD40L and CD134/CD134L in coronary heart disease: A case-control study.
Chen J; Li JH; Zhao SJ; Wang DY; Zhang WZ; Liang WJ
Medicine (Baltimore); 2017 Aug; 96(32):e7634. PubMed ID: 28796044
[TBL] [Abstract][Full Text] [Related]
16. CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma.
Xie F; Shi Q; Wang Q; Ge Y; Chen Y; Zuo J; Gu Y; Deng H; Mao H; Hu Z; Zhou Y; Zhang X
J Neuroimmunol; 2010 May; 222(1-2):62-9. PubMed ID: 20303602
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
[TBL] [Abstract][Full Text] [Related]
18. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
Mineo JF; Bordron A; Baroncini M; Maurage CA; Ramirez C; Siminski RM; Berthou C; Dam Hieu P
J Neurooncol; 2007 Dec; 85(3):281-7. PubMed ID: 17571214
[TBL] [Abstract][Full Text] [Related]
19. Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients.
Akiyama Y; Komiyama M; Miyata H; Yagoto M; Ashizawa T; Iizuka A; Oshita C; Kume A; Nogami M; Ito I; Watanabe R; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Apr; 31(4):1683-90. PubMed ID: 24573400
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H
Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
